The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).
 
Nimer Alsaid
No Relationships to Disclose
 
Ali McBride
Honoraria - Incyte; Takeda
Consulting or Advisory Role - BMS Brazil
 
Daniel Oscar Persky
Consulting or Advisory Role - Cardinal Health; Genentech; MorphoSys; Spectrum Pharmaceuticals; Verastem
Speakers' Bureau - Gilead Sciences
Research Funding - Merck (Inst)
 
Faiz Anwer
No Relationships to Disclose
 
Leslie Ann Andritsos
Consulting or Advisory Role - AstraZeneca
Research Funding - Sanofi
 
Abhijeet Kumar
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Takeda
 
Seongseok Yun
No Relationships to Disclose
 
Hani M. Babiker
Consulting or Advisory Role - Celgene; Endocyte
 
Ivo Abraham
No Relationships to Disclose